Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
Active, not recruiting
Verona Pharma Inc
Phase 2
2020-09-04
This pilot study is being performed to assess the efficacy and safety of inhaled ensifentrine
delivered via pMDI compared with a matching placebo in conjunction with standard of care
treatments on recovery in patients hospitalized due to COVID-19 infection.
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Recruiting
Iqvia Pty Ltd
Phase 3
2020-09-29
The purpose of this study is to determine if ensifentrine is safe and effective for the
treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Recruiting
Verona Pharma plc
Phase 3
2020-09-29
The purpose of this study is to determine if ensifentrine is safe and effective for the
treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Recruiting
Iqvia Pty Ltd
Phase 3
2020-09-22
The purpose of this study is to determine if ensifentrine is safe and effective for the
treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Recruiting
Verona Pharma plc
Phase 3
2020-09-22
The purpose of this study is to determine if ensifentrine is safe and effective for the
treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Not yet recruiting
University of Alabama at Birmingham
Phase 2
2022-04-01
This is a single center, randomized, double-blind, placebo-controlled, two-period cross-over
study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment
Periods. All participants with receive both ensifentrine and placebo during participation.
There are 7 in-clinic visits over a total duration of up to 24 weeks participation.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
